Navigation Links
Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies

According to a study done by Kate Rittenhouse-Olson, Ph.D., the monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend// significantly the survival of mice with human breast-cancer tumors.

The study also finds that the antibody inhibits the cancer's spread to the lungs in the animals by more than 50 percent. The results of this study were published in the November 2006 issue of Journal Neoplasia.

The antibody, named JAA-F11, targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. While the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to adhere to organ tissue, the research showed.

Mice with breast-cancer tumors that received the antibody had a median survival time of 72 days, compared to 57 days for the animals that did not receive JAA-F11, the study found. In addition, exposing cultures of tumor cells to the antibody inhibited cell growth by a statistically significant 16 percent.

Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences, is senior author on the study.

"This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process," said Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing."

The antibody was tested using in vitro models of tumor cell growth, in assays to determine its ability to damage or kill cells (cytotoxicity), in various models of cancer metastasis, and, finally, in mice with metastatic breast cancer.

"In addition to providing a survival advantage," said Rittenhouse-Olson, "JAA-F11 immunothera
'"/>




Page: 1 2

Related medicine news :

1. Long-Term Survival can be Predicted by a Simple Lung Test
2. Hepatitis G May Boost HIV Survival
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Longer Lung Cancer Survival
5. ICU Survival can be improved by Antibiotic use
6. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
7. Improving Survival Rate Of Lung Cancer Patients
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Symptoms Found To Be A Good Predictor Of Cancer Survival
10. Survival Of Colon Cancer Patients
11. Public Defibrillators Found To Improve Survival Rate
Post Your Comments:
(Date:10/6/2008)...erville-based civil litigation and criminal defens...after jury awarded $3.2 million to plaintiff earli...e, Maryland ((Lexis Nexis) October 6, 2008 -- Atto...[Miller, Murtha & Psoras] have successfully re... Maryland welder who was awarded more than $3 mill...
(Date:10/5/2008)...ore healthy choices at schools, standard offerings...e giving students more calories than they need. ,...ide effort led by Temple University to curb obesit...ound vending machines beverages had added sugars, ...over 200 hundred calories. , The data will be pr...
(Date:10/5/2008)...cription drug samples distributed to children may ... Cambridge Health Alliance and Hasbro Children,s H...free drug sample use among children, appears in th...hors, who also serve as researchers at Harvard Med...f Brown University, found that children commonly r...
(Date:10/5/2008)...ized kids with painful ailments from broken bones ... drugs known as opiates. The medications block pai...ion, for instance, is one side effect that can cau...stay. , "No parent wants their child in the hosp... MD, MPH, medical director for quality management ...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:School vending machines dole out excess calories, fat 2Health News:Free drug samples carry risks for children 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 2Health News:Major study of opiate use in children's hospitals provides simple steps to alleviate harm 3
...s that the risk of depression increases in women w...ls who are insulin-resistant may have higher serot...ression and even suicide. Researchers say Insu...with depression and that their results are consist...
...als that a tonsillectomy procedure using less ener... to reducing pain during recovery. // During a to...cial scalpel heats tissue as it goes along to cont...e microdissection needle technique uses less energ...
...s a vaccine made from the common cold virus may in...s.//Researchers from the Centers for Disease Contr...tically altered cold virus that is similar to part...ronavirus, called SARS-CoV, was discovered earlier...
...ws taking vitamin D and consuming a diet high in f...t can lead to colon cancer.// Researchers from 13...n 3,100 patients between ages 50 and 75. Results o...e than four grams of cereal fiber per day and more...
Other Medicine News:Health News:Preventing Colorectal Cancer 2
(Date:10/6/2008)...ntific Conference -, ORLANDO, Fla., Oct. 6 /PRNew...bia) today announced presentation of data from a p...at cyclic guanosine,monophosphate (cGMP) plays in ...rate that cGMP inhibits intestinal pain in a precl...itizes colonic afferent nerves in a,similar model ...
(Date:10/6/2008)...py is More Likely to Induce Steroid-Free Remissi... Immunomodulator, Azathioprine, OR... for the first time,from the Phase 3b Study of Pat...rs and Biologic Therapy (SONIC) may provide new in...moderate to severe Crohn,s disease.,According to f...
(Date:10/6/2008)...Naltrexone SR Associated with Bette.... 6 /- Orexigen Therapeutic...any focused on the treatment of,obesity and other ...esented,data showing the investigational drug, Con...lly achieved key objectives (lowered naltrexone,Cm...
(Date:10/5/2008)...f Medicine reaffirm,well-established efficacy and ...R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNe...tential Long-term Impacts on Function with,Tiotrop...tiotropium bromide,inhalation powder), sustained i...measured by FEV(1) (p<0.001) versus placebo in Chr...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 1Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 2Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 3Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 4Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 5Regular exercise reduces risk of blood clots 6712 1Evolutionary comparison finds new human genes 1289 1Evolutionary comparison finds new human genes 1289 2Evolutionary comparison finds new human genes 1289 3New book presents methods to poke and prod individual molecules 1284 1New book presents methods to poke and prod individual molecules 1284 2
... -- Novagali Pharma, an,emerging ophthalmic pharma...ounces today positive results from the Phase III,c...from Vernal,Keratoconjunctivitis (VKC). In this or...signs of disease improved in patients,receiving Ve...(R),was excellent. , VKC is a severe form of chron...
...f the International,Society on Thrombosis and Haem...07 /PRNewswire/ --,Portola Pharmaceuticals, Inc. t...ts from EXPERT, a Phase II study of its oral Facto...enous,thromboembolism (VTE) following total knee r...Portola will advance PRT054021,into further clinic...
Other Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 3
With this unique offer, you can prepare for any molecular biology application. Pipetman P2 and P10 are ideal for enzymes and reagents, and P100 is perfect for buffers. Kits include Diamond Filter Tip
The RapidPCP test is an immunochromatography based one step in vitro test. It is,designed for qualitative determination of Phencyclidine in human urine specimens above,a cut-off level of 25 ng/mL. Th
... an immunochromatography based one step,in vitro t...of Opiates and its metabolite in,human urine speci...e a cut-off level,of 2,000ng/mL can be detected. T...are,location and is for use by Healthcare Professi...
All of DOA Panel Test is an immunochromatography based one step in vitro test. It is designed,for qualitative determination of drug substances in human urine specimens. This assay has not,been evalua
Medicine Products: